Context Whether prostate-specific membrane antigen positron emission tomography (PSMA-
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

After prostate malignancy diagnosis, precise determination of disease extent are
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …

In the past two decades, extensive efforts have been made to develop agents targeting
prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To …

In the past decades, the expanding use of prostate-specific membrane antigen (PSMA)
imaging for prostate cancer has led to the incidental detection of a lot of extra-prostatic …

Simple Summary Imaging plays a crucial role in the accurate staging of prostate cancer.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …

Cancer cells are surrounded by a complex and highly dynamic tumor microenvironment
(TME). Cancer-associated fibroblasts (CAFs), a critical component of TME, contribute to …

Biochemical recurrence develops in almost one-third of men with prostate cancer after
treatment with local therapy. There are numerous options for management, including …

Background Prostate-specific membrane antigen (PSMA) PET is standard for newly
diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. Although studies …

Simple Summary The combination of positron emission tomography (PET)-diagnostics with
ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic …